Pipelines

(Image: Getty/Milkos)

BIO-Europe Spring

Finding treatment solutions where there are none

By Ben Hargreaves

The industry focuses investments where there is the highest potential returns, but one panel at BIO-Europe Spring suggested multiple partners could boost outcomes in underserved therapeutic areas.

(Image: Getty/Ktsimage)

Regeneron in $1bn RNAi pact with Alnylam

By Ben Hargreaves

Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.

(Image: Getty/Dragana991)

A troubled timeline of Alzheimer’s trials

By Ben Hargreaves

After Biogen’s setback in the space, the number of treatments that have not succeeded in making an impact on Alzheimer’s disease continues to grow.

Follow us

Products

View more

Webinars